Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. August 2022 10:30 ET | Quelle: Alphageneron Pharmaceuticals

Alphageneron to Participate in Cell Therapy Durability Response Summit

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company developing a diverse platform of...
18. Oktober 2021 10:58 ET | Quelle: Alphageneron Pharmaceuticals

Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients

CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company with a robust product portfolio of...
25. Juni 2021 19:21 ET | Quelle: Alphageneron Pharmaceuticals

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held clinical-stage biopharmaceutical company developing...
04. Februar 2021 11:35 ET | Quelle: Alphageneron Pharmaceuticals

Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on...